HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma.

AbstractPURPOSE:
The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformality is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the As Low As Reasonably Practicable principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference.
METHODS AND MATERIALS:
A literature search on dose tolerances and normal-tissue complications after treatment for nasopharyngeal carcinoma was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then recirculated to the whole panel for review and reconsideration. Based on the comments of the panel, a refined second proposal was recirculated to the same panel. The current guideline was based on majority voting after repeated iteration for final agreement.
RESULTS:
Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed.
CONCLUSIONS:
Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and the patient's acceptance of optimal balance of risk.
AuthorsAnne W Lee, Wai Tong Ng, Jian Ji Pan, Chi-Leung Chiang, Sharon S Poh, Horace C Choi, Yong Chan Ahn, Hussain AlHussain, June Corry, Cai Grau, Vincent Grégoire, Kevin J Harrington, Chao Su Hu, Dora L Kwong, Johannes A Langendijk, Quynh Thu Le, Nancy Y Lee, Jin Ching Lin, Tai Xiang Lu, William M Mendenhall, Brian O'Sullivan, Enis Ozyar, Lester J Peters, David I Rosenthal, Giuseppe Sanguineti, Yoke Lim Soong, Yungan Tao, Sue S Yom, Joseph T Wee
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 105 Issue 3 Pg. 567-580 (11 01 2019) ISSN: 1879-355X [Electronic] United States
PMID31276776 (Publication Type: Journal Article, Practice Guideline, Systematic Review)
CopyrightCopyright © 2019 Elsevier Inc. All rights reserved.
Topics
  • Delphi Technique
  • GRADE Approach
  • Humans
  • International Cooperation
  • Nasopharyngeal Carcinoma (pathology, radiotherapy)
  • Nasopharyngeal Neoplasms (pathology, radiotherapy)
  • Neoplasm Recurrence, Local
  • Organs at Risk (radiation effects)
  • Radiation Injuries (prevention & control)
  • Radiotherapy Dosage
  • Radiotherapy Planning, Computer-Assisted
  • Radiotherapy, Intensity-Modulated
  • Tumor Burden

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: